Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Mov Disord. 2003 Oct;18(10):1149-56. doi: 10.1002/mds.10508.

Abstract

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living
  • Aged
  • Antiparkinson Agents / therapeutic use*
  • Benzothiazoles
  • Bromocriptine / therapeutic use*
  • Demography
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Administration Schedule
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / drug therapy*
  • Pramipexole
  • Prospective Studies
  • Quality of Life
  • Thiazoles / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Benzothiazoles
  • Thiazoles
  • Bromocriptine
  • Pramipexole